罗氟司特(Roflumilast)价格是多少钱

Roflumilast is a drug used to treat chronic obstructive pulmonary disease (COPD), especially in patients with a history of chronic bronchitis. This article will introduce in detail the price, usage and dosage of roflumilast, and its listing status. By knowing this information, patients and medical professionals can better understand the economics and use of this medication.

How much does Roflumilast cost?

The price varies according to different regions and specifications. The following is the reference price of Roflumilast produced by AstraZeneca in the UK in different regions for reference only.

Price of the German version of AstraZeneca in the UK

Roflumilast produced by AstraZeneca in the UK, the export specification for the German version is 500μg*30 tablets, and the reference price is about US$233 per box. The specification is 500μg*90 tablets, and the reference price is about US$391 per box. These prices may vary by pharmacy and purchase channel.

The price of the Hong Kong version of AstraZeneca in the UK

The Hong Kong version of Roflumilast produced by AstraZeneca in the UK is exported to 500μg*30 tablets, and the reference price is about US$134 per box. Prices in Hong Kong are relatively low and may be more suitable for patients with limited budgets.

Understanding the price of roflumilast can help patients make more informed decisions when choosing treatment options, and the price differences in different regions also provide patients with more choices.

Roflumilast usage and dosage

The usage and dosage of Roflumilast need to be determined according to the patient’s specific situation and the doctor’s advice. The following is some basic information about the usage and dosage of Roflumilast.

Conventional dosage

The conventional recommended dosage of roflumilast is 500 μg once daily. Patients should take it at the same time every day to ensure that the concentration of the drug in the body remains stable.

Dose adjustment in special populations

For patients with hepatic impairment, dose adjustment may be necessary. The doctor will decide whether to reduce the dose or extend the medication interval based on the patient's specific situation.

Drug Precautions

Patients should avoid drinking alcohol while taking roflumilast, because alcohol may increase the side effects of the drug. At the same time, patients should undergo regular liver function tests to monitor the safety of the drug.

Patients should strictly follow the doctor's instructions and avoid adjusting the dosage on their own.

Roflumilast’s marketing status

Roflumilast has been approved for marketing in many countries and regions. Below are some details about the availability of roflumilast.

U.S. market

Roflumilast was approved by the FDA in the United States in 2011 for the treatment of COPD. Its launch in the U.S. market provides patients with a new treatment option.

European market

Roflumilast has been approved in many European countries, including Germany, the United Kingdom and France. The drug's efficacy and safety are demonstrated by its broad acceptance on the European market.

Asian market

Roflumilast has also been launched in many Asian countries and regions, such as Japan and Hong Kong, China. The launch in the Asian market further expands the drug's global reach.

The global marketing status of roflumilast reflects its important position in the treatment of COPD. As more countries and regions recognize the drug, patients will have easier access to this effective treatment.